Traumatic Brain Injury | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2015

A sudden, mechanical head injury that disrupts brain function is termed traumatic brain injury (TBI). Motor vehicle accidents, violence, and falls are the most common causes of TBI. Symptoms such as headache, fatigue, and mood changes can occur across TBI severities. However, in moderate to severe TBI these symptoms may be compounded by progressively worsening headaches, inability to awaken from sleep, agitation, and seizures, among others. Disabilities resulting from TBI depend on the extent of brain damage—cognition deficits and mental health problems are common; in the extreme, severe TBI patients may be in a vegetative state. With no neuroprotective therapies currently available, the treatment goal in TBI is to prevent further brain damage. Surgery may be required for brain hematomas or contusions, and moderate to severe cases require rehabilitation tailored to patients’ specific TBI manifestations.

Questions Answered:

• The number of diagnosed TBI events will increase slightly over the 2014-2024 forecast period. What is the number of diagnosed TBI events in the United States and the five major European markets (France, Germany, Italy, Spain, and the United Kingdom)? How will the number of diagnosed TBI events change over the ten-year forecast period? How many diagnosed TBI events are classified mild, moderate, or severe at this time and through 2024?
• Research into the pathophysiological basis of TBI has revealed various, complicated signaling cascades. What new insights are informing experts’ understanding of TBI? What are the key avenues of TBI preclinical and clinical research and drug development efforts?
• Unmet needs in TBI span a range of challenging issues. What are the emerging TBI therapies in late-stage development and to what degree could they address the unmet need in TBI? What are the key primary and secondary clinical end points on which new therapies are evaluated and how do interviewed experts perceive these end points?

Scope:

Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Eight country-specific interviews with thought-leading neurologists.

Epidemiology: Total diagnosed events of TBI, diagnosed events of TBI by severity, by gender, and by treatment setting.

Emerging therapies: Phase III: 1; Phase II: 5; coverage of select preclinical and Phase I products.